Browse drugs

…n use, and engaging clinical teams. Results show evidence-based albumin use rose from 45.4% to 87.8%, saving $76,000 and improving care…

…rs, range 1–12) were included and received a single low dose of rituximab. Among the nine patients treated, seven were acetylcholine rece…

…zing antibodies, and intestinal macrophages were depleted using clodronate liposomes. Additionally, the potential impact of these immune cells and s…

…binding to its promoter. Pharmacological inhibition of FXR with UDCA reversed T-cell exhaustion, and synergized with anti-PD-L1 ther…

…ients from the INCREASE trial who were treated with neoadjuvant ipilimumab/nivolumab (IPI/NIVO) plus chemoradiotherapy (CRT) (n=25) and (2) a matche…

…is COX-2-Is do not have broad regulatory approval; for example, parecoxib has not been approved by the US Food and Drug Administration an…

…FI: −2.9) and HRQoL (SF-36 PCS: +12.4; ASQoL: −5.6).Conclusions Bimekizumab treatment resulted in sustained improvements in patient-reporte…

…ith 95% CIs of suicidal behaviour and depression in women using hormonal contraceptives.Results We followed more than two million women for a median of…

…y dizziness was carried out. Patients were given treatment with 1g IV Mg following review by consultant neurologists. Outcomes were asse…

…second panel meeting and compound ranking repeated, as follows: Atomoxetine (1st), Metformin (2nd), Isosorbide Mononitrate and Levetiraceta…

…ere identified as obese, of which 102/113 (90%) were prescribed aciclovir doses higher than their IBW-adjusted dose. We found an incidenc…

…ts with generalised myasthenia gravis (gMG) received one 6-week rozanolixizumab treatment cycle. All patients who enrolled in MG0007 (NCT046508…